Eton Pharmaceuticals (NASDAQ:ETON) Releases Quarterly Earnings Results, Beats Expectations By $0.19 EPS

Eton Pharmaceuticals (NASDAQ:ETON) announced its quarterly earnings results on Thursday. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.19, FiscalAI reports. The company had revenue of $57.93 million for the quarter, compared to analysts’ expectations of $41.98 million. Eton Pharmaceuticals had a net margin of 35.35% and a return on equity of 144.74%.

Here are the key takeaways from Eton Pharmaceuticals’ conference call:

• Eton reported record third-quarter revenue of $57.9 million, up 158% year over year, with growth from HEMANGEOL and strength across its portfolio. The company raised 2026 revenue guidance to more than $175 million.
• Profitability and cash generation improved sharply: adjusted gross margin was 80%, adjusted EBITDA was $28.5 million (49% of revenue), and cash from operations was $35 million. Eton ended the quarter with $55.6 million in cash after a $5 million debt prepayment, and now expects a full-year adjusted EBITDA margin above 40%.
• LIBERVANT adds a potential near-term growth driver in seizure-cluster treatment; Eton expects to launch in April 2027, subject to FDA approval and resolution of exclusivity restrictions. Management sees opportunity for its portable buccal film in a U.S. market it estimates exceeds $450 million annually.
• Management sees significant pipeline upside, particularly from ASN-001, a topical hemangioma treatment it believes could serve a broader population than HEMANGEOL; a short bioavailability study is underway, with an NDA submission targeted for mid-2027 and a potential 2028 launch. Other programs include a planned 2027 study of ET-900 for infantile spasms and a potential 2027 launch for glibenclamide oral suspension.
• ET-700’s proof-of-concept study found treatment-related adverse events in 1 of 12 participants versus 8 of 12 on GALZIN, but it blocked copper absorption less effectively than GALZIN. Eton attributed the efficacy gap to a release profile it says was too slow and plans to test faster-release formulations in 2027, leaving the program’s next steps dependent on further results.

Eton Pharmaceuticals Stock Performance

Shares of NASDAQ ETON traded up $9.31 during trading on Friday, reaching $56.46. 1,269,987 shares of the company traded hands, compared to its average volume of 415,837. The firm’s fifty day simple moving average is $54.80 and its 200 day simple moving average is $36.46. The stock has a market cap of $1.61 billion, a P/E ratio of 37.39 and a beta of 0.89. Eton Pharmaceuticals has a 12-month low of $14.27 and a 12-month high of $66.37. The company has a current ratio of 1.52, a quick ratio of 1.30 and a debt-to-equity ratio of 0.41.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ETON shares. B. Riley Financial restated a “buy” rating and issued a $70.00 target price (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. HC Wainwright lifted their price target on shares of Eton Pharmaceuticals from $70.00 to $80.00 and gave the company a “buy” rating in a research note on Friday. Canaccord Genuity Group raised their price objective on Eton Pharmaceuticals from $68.00 to $80.00 and gave the stock a “buy” rating in a report on Friday. Craig Hallum restated a “buy” rating and set a $78.00 price target on shares of Eton Pharmaceuticals in a research note on Thursday, October 15th. Finally, Zacks Research raised shares of Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 12th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $77.00.

Insider Buying and Selling

In related news, insider David Krempa sold 25,000 shares of the company’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $65.07, for a total transaction of $1,626,750.00. Following the completion of the sale, the insider owned 37,025 shares of the company’s stock, valued at approximately $2,409,216.75. This represents a 40.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Paul V. Maier sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $59.07, for a total value of $2,953,500.00. Following the transaction, the director owned 59,745 shares in the company, valued at approximately $3,529,137.15. This represents a 45.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 79,166 shares of company stock valued at $4,809,672 over the last three months. 16.49% of the stock is currently owned by corporate insiders.

More Eton Pharmaceuticals News

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Q3 product sales reached a record $57.9 million, up 158% year over year. Eton reported diluted GAAP EPS of $1.06 and non-GAAP EPS of $0.50, and said it exceeded a $200 million annualized revenue run rate five quarters ahead of schedule. Eton Q3 results
• Positive Sentiment: Management raised its 2026 revenue outlook to more than $175 million, from more than $145 million, and lifted its adjusted EBITDA margin outlook to above 40%, from above 35%. The stronger forecast reinforces expectations for continued growth and improving profitability. Eton earnings and guidance
• Positive Sentiment: Canaccord Genuity and HC Wainwright both raised their price targets to $80 and maintained Buy ratings, signaling confidence in Eton’s prospects. Canaccord Genuity rating HC Wainwright rating
• Neutral Sentiment: Eton announced preliminary results from an ET-700 pilot study assessing copper absorption inhibition and gastrointestinal tolerability. The brief report does not provide enough detail to judge the findings’ significance for the pipeline. ET-700 pilot study update

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.